All In Biotech

Drug Trial Radar · NCT05631704

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single and Multiple Ascending Dose First-Time-in-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Dec 2, 2022

Primary completion

Jul 27, 2023

Study completion Jul 27, 2023

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy participants.

Conditions

  • HIV Infections

Interventions

  • VH4524184Drug

    VH4524184 will be administered.

  • MidazolamDrug

    Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants with serious adverse events (SAE) and non-serious adverse events (non-SAE)Time frame: Up to 4 weeks
  2. Part 2: Number of participants with SAE and non-SAETime frame: Up to 6.5 weeks
  3. Part 3: Number of participants with SAE and non-SAETime frame: Up to 6.5 weeks
  4. Part 1: Number of participants with adverse events based on severityTime frame: Up to 4 weeks
  5. Part 2: Number of participants with adverse events by severityTime frame: Up to 6.5 weeks
  6. Part 3: Number of participants with adverse events based on severityTime frame: Up to 6.5 weeks
  7. Part 1: Percentage of participants who discontinue treatment due to adverse events (AE)Time frame: Up to 4 weeks
  8. Part 2: Percentage of participants who discontinue treatment due to AETime frame: Up to 6.5 weeks
  9. Part 3: Percentage of participants who discontinue treatment due to AETime frame: Up to 6.5 weeks
  10. Part 1: Change from Baseline in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) (International units per liter)Time frame: Baseline (Day 1) and up to 4 weeks
  11. Part 2: Change from Baseline in AST, ALT and ALP (International units per liter)Time frame: Baseline (Day 1) and up to 6.5 weeks
  12. Part 3: Change from Baseline in AST, ALT and ALP (International units per liter)Time frame: Baseline (Day 1) and up to 6.5 weeks
  13. Part 1: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)Time frame: Baseline (Day 1) and up to 4 weeks
  14. Part 2: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)Time frame: Baseline (Day 1) and up to 6.5 weeks
  15. Part 3: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)Time frame: Baseline (Day 1) and up to 6.5 weeks
  16. Part 1: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)Time frame: Baseline (Day 1) and up to 4 weeks
  17. Part 2: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)Time frame: Baseline (Day 1) and up to 6.5 weeks
  18. Part 3: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)Time frame: Baseline (Day 1) and up to 6.5 weeks
  19. Part 1: Change from Baseline in International normalized ratio (INR) (Ratio)Time frame: Baseline (Day 1) and up to 4 weeks
  20. Part 2: Change from Baseline in INR (Ratio)Time frame: Baseline (Day 1) and up to 6.5 weeks
  21. Part 3: Change from Baseline in INR (Ratio)Time frame: Baseline (Day 1) and up to 6.5 weeks
  22. Part 1: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INRTime frame: Baseline (Day 1) and up to 4 weeks
  23. Part 2: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INRTime frame: Baseline (Day 1) and up to 6.5 weeks
  24. Part 3: Number of participant with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INRTime frame: Baseline (Day 1) and up to 6.5 weeks
  25. Part 1: Area under the plasma-concentration time curve from zero (pre-dose) extrapolated to infinite time (AUC[0-infinity]) following dosing of VH4524184Time frame: Up to 4 weeks
  26. Part 2: Area under the plasma concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tau]) following dosing of VH4524184Time frame: Up to 6.5 weeks
  27. Part 1: Maximum observed plasma drug concentration (Cmax) following dosing of VH4524184Time frame: Up to 4 weeks
  28. Part 2: Cmax following dosing of VH4524184Time frame: Up to 6.5 weeks
  29. Part 1: Time to maximum observed plasma drug concentration (tmax) following dosing of VH4524184Time frame: Up to 4 weeks
  30. Part 2: Tmax following dosing of VH4524184Time frame: Up to 6.5 weeks
  31. Part 1: Apparent terminal half-life (t1/2) following dosing of VH4524184Time frame: Up to 4 weeks
  32. Part 2: T1/2 following dosing of VH4524184Time frame: Up to 6.5 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.